BRPI0924061A2 - Intensificadores de angiogenese gerada por acidente vascular cerebral e usos dos mesmos - Google Patents

Intensificadores de angiogenese gerada por acidente vascular cerebral e usos dos mesmos

Info

Publication number
BRPI0924061A2
BRPI0924061A2 BRPI0924061-6A BRPI0924061A BRPI0924061A2 BR PI0924061 A2 BRPI0924061 A2 BR PI0924061A2 BR PI0924061 A BRPI0924061 A BR PI0924061A BR PI0924061 A2 BRPI0924061 A2 BR PI0924061A2
Authority
BR
Brazil
Prior art keywords
enhancers
stroke
stroke angiogenesis
angiogenesis enhancers
angiogenesis
Prior art date
Application number
BRPI0924061-6A
Other languages
English (en)
Inventor
Gregory J Bix
Original Assignee
Texas A & M Univ Sys
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texas A & M Univ Sys filed Critical Texas A & M Univ Sys
Publication of BRPI0924061A2 publication Critical patent/BRPI0924061A2/pt
Publication of BRPI0924061B1 publication Critical patent/BRPI0924061B1/pt
Publication of BRPI0924061B8 publication Critical patent/BRPI0924061B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0924061A 2008-12-31 2009-12-31 composicão farmacêutica compreendendo uma proteína endorepellin BRPI0924061B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20406408P 2008-12-31 2008-12-31
US61/204,064 2008-12-31
PCT/US2009/006758 WO2010077364A2 (en) 2008-12-31 2009-12-31 Stroke-generated angiogenesis enhancers and uses thereof

Publications (3)

Publication Number Publication Date
BRPI0924061A2 true BRPI0924061A2 (pt) 2015-07-07
BRPI0924061B1 BRPI0924061B1 (pt) 2020-11-24
BRPI0924061B8 BRPI0924061B8 (pt) 2021-05-25

Family

ID=42174116

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0924061A BRPI0924061B8 (pt) 2008-12-31 2009-12-31 composicão farmacêutica compreendendo uma proteína endorepellin

Country Status (12)

Country Link
US (1) US8466105B2 (pt)
EP (1) EP2373328B1 (pt)
JP (1) JP5591825B2 (pt)
KR (1) KR101746749B1 (pt)
CN (2) CN102355905A (pt)
AU (1) AU2009333815B2 (pt)
BR (1) BRPI0924061B8 (pt)
CA (1) CA2748811C (pt)
ES (1) ES2524366T3 (pt)
MX (1) MX2011007108A (pt)
RU (1) RU2011131772A (pt)
WO (1) WO2010077364A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9358273B2 (en) 2010-01-06 2016-06-07 The Texas A&M University System Use of perlecan domain V in treating amyloidogenic disease
US9072713B2 (en) 2010-07-01 2015-07-07 The Texas A&M University System Perlecan domain V protects, repairs and restores ischemic brain stroke injury and motor function
WO2019118689A1 (en) * 2017-12-13 2019-06-20 University Of Kentucky Research Foundation Compositions and methods for enhancing neuro-repair
CN108715833B (zh) * 2018-06-01 2021-09-14 天晴干细胞股份有限公司 一种负载血小板裂解液的微球制备方法
AU2021314398A1 (en) * 2020-07-24 2023-03-23 Stream Biomedical, Inc. Use of perlecan and fragments thereof to reduce the risk of death in stroke patients

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6821947B2 (en) * 2001-12-04 2004-11-23 Thomas Jefferson University Endorepellin: methods and compositions for inhibiting angiogenesis

Also Published As

Publication number Publication date
MX2011007108A (es) 2011-09-28
CN102355905A (zh) 2012-02-15
AU2009333815A1 (en) 2011-08-11
JP5591825B2 (ja) 2014-09-17
BRPI0924061B8 (pt) 2021-05-25
EP2373328B1 (en) 2014-08-20
CA2748811C (en) 2019-07-16
ES2524366T3 (es) 2014-12-05
US8466105B2 (en) 2013-06-18
WO2010077364A3 (en) 2010-10-21
KR101746749B1 (ko) 2017-06-13
US20100168025A1 (en) 2010-07-01
BRPI0924061B1 (pt) 2020-11-24
AU2009333815B2 (en) 2016-02-18
WO2010077364A2 (en) 2010-07-08
EP2373328A2 (en) 2011-10-12
KR20110127131A (ko) 2011-11-24
JP2012514036A (ja) 2012-06-21
RU2011131772A (ru) 2013-02-10
CN104208659A (zh) 2014-12-17
CA2748811A1 (en) 2010-07-08

Similar Documents

Publication Publication Date Title
BRPI0818477A2 (pt) Dc-sign, icam-3 e lsectin porcinos e usos dos mesmos
BRPI0914682A2 (pt) compostos de heteroarila e usos dos mesmos
BRPI0920927A2 (pt) derivados de azaquinolinona e usos dos mesmos
BRPI0922689A2 (pt) conjugados de neurotensina ou análogos de neurotensina e usos dos mesmos
BRPI0912198A2 (pt) anticorpos anti-fn14 e usos dos mesmos
BRPI0911656A2 (pt) formulações de nanopartículas e usos das mesmas
BRPI1009455A2 (pt) anticorpos anti-c40 e usos dos mesmos
BRPI0914891A2 (pt) agonistas de aril gpr119 e usos dos mesmos
BRPI1014997A2 (pt) compostos heteroarila e usos dos mesmos
BRPI1013943A2 (pt) Composto cetais e usos dos mesmos.
BRPI0922691A2 (pt) conjugados de leptina e análogo de leptina e usos dos mesmos
BRPI1011404A2 (pt) mutantes e usos dos mesmos
BRPI1011970A2 (pt) compostos pirazolil-acrilonitrila e usos dos mesmos.
BRPI0913574A2 (pt) composição de tratamento de acne compreendendo nanoprata e usos
FI20085238A (fi) Kehon sisäinen luudistraktiolaite
BRPI0920209A2 (pt) conjugados de agonistas de glp-1 e usos dos mesmos
BRPI0914341A2 (pt) artigos absorventes descartáveis para sexo específico
BRPI0817269A2 (pt) Análogos de azacitidina e usos dos mesmos
BR112013015592A8 (pt) derivados de biciclo-[3.2.1]-octilamida e usos dos mesmos
BR112012001260A2 (pt) conjugados de epsilon-polilisina e o emprego dos mesmos
BR112012015873A2 (pt) antagonistas de receptores ccr2 e usos dos mesmos
BRPI0822337A2 (pt) Folatos, composições e usos dos mesmos
FI20095433A0 (fi) Mikroneula
BRPI0920392A2 (pt) reservatório de sangue
BRPI0921230A2 (pt) agonistas de receptor de neuropeptídeos-2 (y-2r) e usos dos mesmo.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/12/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF